The landmark ASTRUM-007 trial established serplulimab as a first-line therapeutic option for advanced ESCC patients with PD-L1 CPS ≥ 1, demonstrating robust efficacy and manageable safety within a strictly controlled trial setting (10). The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.